1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 4: Clinical results in the particular subgroups
EKOS MCA Control MCA P EKOS BA Control BA P
Baseline NIHSS (median) (IQR) 15 (10–18) 15.5 (12–20) <.05 27 (14.5–33) 24 (12–32) <.05
NIHSS 24 hr (median) (IQR) 4 (2–6) 16 (12–20) .0001 10 (7–25) 24 (14–28) <.05
NIHSS day 7 (median) (IQR) 2 (1.5–4) 15.5 (7–20) .0001 6 (4.5–19) 33 (8–33) .049
Presence of ENI after 24 hours (No.) (%) 7 (100%) 2 (4.6%) .0001 4 (57.1%) 2 (16.7%) <.05
90-day mRS (median) (IQR) 1 (1–3.5) 5 (3–5) .037 3 (2–4.5) 6 (4.5–6) .034
mRS 0–3 at day 90 (No.) (%) 5 (71.4%) 8 (18.2%) .008 4 (57.1%) 2 (16.7%) <.05
mRS 0–2 at day 90 (No.) (%) 5 (71.4%) 6 (13.6%) .003 2 (28.6%) 2 (16.7%) <.05
SICH (No.) (%) 0 (0%) 1 (2.3%) <.05 0 (0%) 1 (8.3%) <.05
Malignant infarction (No.) (%) 0 (0%) 3 (6.8%) <.05 0 (0%) 0 (0%) <.05
7-day mortality (No.) (%) 0 (%) 3 (6.8%) <.05 0 (%) 6 (50.0%) .044
3-month mortality (No.) (%) 2 (28.6%) 10 (22.7%) <.05 0 (0%) 8 (66.7%) .013
Note:—ENI indicates early neurologic improvement; EKOS, EkoSonic Endovascular System; SICH, symptomatic intracerebral hemorrhage; IQR, interquartile range.